Sumary of Pfizer Says COVID-19 Vaccine Efficacy Weakens Over Time:
- This story originally appeared on The Epoch Times Pfizer said that data from Israel and the United States suggests that its COVID-19 vaccine efficacy drops over time and claimed that booster doses are effective at dealing with new virus variants.
- “Real-world data from Israel and the United States suggest that rates of breakthrough infections are rising faster in individuals who were vaccinated earlier in the vaccination campaigns compared to those who have been vaccinated more recently,” Pfizer said during its presentation this week, which was posted on the FDA website.
- And the evidence from the studies indicates that the “observed decrease of vaccine effectiveness against COVID-19 infections is primarily due to waning of vaccine immune responses over time rather than a result of the Delta variant escaping vaccine protection,” said Pfizer.
- Based on its data, Pfizer said that booster doses should be given to all people aged 16 and older six months after they received their second dose of the mRNA vaccine.
- The pharmaceutical giant, which partnered with BioNTech for its vaccine, cited a study from healthcare giant Kaiser Permanente that suggested protection against COVID-19 infection dropped from 88 percent in the first month of getting the second dose to 47 percent after five months.
- But in a study published by The Lancet on Monday, two senior FDA vaccine reviewers who are expected to leave the agency soon and more than a dozen top researchers argued that booster shots aren’t needed for the general population.
- They argued that potential side-effects from the extra doses could outweigh the benefits, arguing that such a phenomenon would actually increase vaccine hesitance.
- “Even if boosting were eventually shown to decrease the medium-term risk of serious disease, current vaccine supplies could save more lives if used in previously unvaccinated populations,” the authors wrote.